US advocacy group decries shifting of high drug costs to consumers
This article was originally published in Scrip
Executive Summary
AARP, the advocacy group representing mature adults, argues that shifting the costs of expensive speciality and injectable drugs to consumers is a major problem in the US. While consumers are accustomed to paying fixed-dollar co-payments at the pharmacy counter, more and more often they are being asked to pay co-insurance (percentage of the entire prescription’s cost), generally 25-35%.